Pharma News

Another COVID19 vaccine of Zydus enters in human trials

  • Posted on: 4 July 2020
  • By: PharmaTutor News

Zydus an innovation-driven, global pharmaceutical company, announced that it’s plasmid DNA vaccine candidate for COVID-19 (ZyCoV-D) developed indigenously at its Vaccine Technology Centre in Ahmedabad, India has successfully completed the preclinical phase and has now received permission from the Drug Controller General of India - Central Drugs Standard Control Organisation (CDSCO) to initiate Phase I/II human clinical trials in India.

Sun Pharma announces Japan MHLW approval of ILUMYA for the treatment of Plaque Psoriasis

  • Posted on: 2 July 2020
  • By: PharmaTutor News

Sun Pharma and includes its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 430,000 people currently suffering from psoriasis.

FDA approves BAVENCIO as treatment for Metastatic Urothelial Carcinoma

  • Posted on: 1 July 2020
  • By: PharmaTutor News

Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

DCGI gives approval for human clinical trials of COVAXIN

  • Posted on: 30 June 2020
  • By: PharmaTutor News

Drug Controller General of India (DCGI) has given approval for human clinical trials of COVAXIN, the first potential COVID-19 Vaccine developed in India. The potential vaccine has been developed by Hyderabad-based Bharat Biotech, in association with Indian Council for Medical Research (ICMR). Human Trials for Phase I and Phase II are scheduled to start across the country from next month.

Gplife Healthcare obtains Phase II Clinical trial permission for treatment of COVID 19 Positive Patients in India

  • Posted on: 29 June 2020
  • By: PharmaTutor News

Gplife Healthcare Pvt. Ltd. And it’s associate company Shadow Pharma Venture Pvt. Ltd today announced that Gplife Healthcare has obtained Phase II clinical trial permission on ACT 12 Tablets and ACT 13 Dry Syrup for the treatment of COVID 19 positive hospitalized patients. Treatment duration for patients will be 10 days. The results of clinical trial are expected by August 2020. Both products have been found safe at the recommended dose for Phase II study.

INST synthesises inorganic-organic hybrid compound that can inhibit breast, lung & liver cancer cells

  • Posted on: 29 June 2020
  • By: PharmaTutor News

Scientists from the Institute of Nano Science & Technology (INST), Mohali, an autonomous institute of the Department of Science and Technology Government of India, have synthesized a novel inorganic-organic hybrid compound that can inhibit breast, lung, and liver cancer cells, opening up new possibilities for metallodrugs.

Hindustan Unilever completes acquisition of Vwash from Glenmark Pharmaceuticals

  • Posted on: 27 June 2020
  • By: PharmaTutor News

Hindustan Unilever Limited (HUL) announced that it has completed the acquisition of intimate hygiene brand VWash from Glenmark Pharmaceuticals Ltd. This acquisition was announced on March 23, 2020 and was subject to certain closing conditions, which have now been fulfilled.

Pages